These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22357638)

  • 21. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Wen F; Zhang N; Zhou K; Bai L; Li Q
    Breast Cancer; 2020 May; 27(3):399-404. PubMed ID: 31853795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom.
    Das R; Cope S; Ouwens M; Turner P; Howlett M
    Clin Ther; 2013 Mar; 35(3):246-260.e5. PubMed ID: 23453402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
    Le QA; Hay JW
    Cancer; 2009 Feb; 115(3):489-98. PubMed ID: 19117341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.
    Zhang Q; Shao Z; Shen K; Li L; Feng J; Tong Z; Gu K; Wang X; Xu B; Sun G; Chen H; Rukazenkov Y; Jiang Z
    Oncotarget; 2016 Aug; 7(35):57301-57309. PubMed ID: 27359058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
    Wang J; Jain S; Coombes CR; Palmieri C
    Breast J; 2009; 15(3):247-53. PubMed ID: 19645779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
    Jones SE
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):14-20. PubMed ID: 14613022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients.
    Warm M; Kates R; Overkamp F; Thomas A; Harbeck N
    Breast Cancer Res Treat; 2011 Jan; 125(1):127-36. PubMed ID: 20960229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
    Aurilio G; Munzone E; Botteri E; Sciandivasci A; Adamoli L; Minchella I; Esposito A; Cullurà D; Curigliano G; Colleoni M; Goldhirsch A; Nolè F
    Breast J; 2012 Sep; 18(5):470-4. PubMed ID: 22827581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.
    Litsas G
    Clin J Oncol Nurs; 2011 Dec; 15(6):674-81. PubMed ID: 22119979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormonal therapy for breast cancer: focus on fulvestrant.
    Versea L; Rosenzweig M
    Clin J Oncol Nurs; 2003; 7(3):307-11. PubMed ID: 12793337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
    Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of fulvestrant in the management of postmenopausal breast cancer.
    Krell J; Januszewski A; Yan K; Palmieri C
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1641-52. PubMed ID: 22050013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.